178 related articles for article (PubMed ID: 21712434)
1. Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats.
Yamaguchi K; Kato M; Suzuki M; Asanuma K; Aso Y; Ikeda S; Ishigai M
Drug Metab Dispos; 2011 Oct; 39(10):1801-7. PubMed ID: 21712434
[TBL] [Abstract][Full Text] [Related]
2. In vitro-in vivo correlation of the inhibition potency of sodium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach.
Yamaguchi K; Kato M; Suzuki M; Hagita H; Takada M; Ayabe M; Aso Y; Ishigai M; Ikeda S
J Pharmacol Exp Ther; 2013 Apr; 345(1):52-61. PubMed ID: 23386251
[TBL] [Abstract][Full Text] [Related]
3. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
4. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.
Pessoa TD; Campos LC; Carraro-Lacroix L; Girardi AC; Malnic G
J Am Soc Nephrol; 2014 Sep; 25(9):2028-39. PubMed ID: 24652792
[TBL] [Abstract][Full Text] [Related]
5. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
6. A fluorescence method for measurement of glucose transport in kidney cells.
Blodgett AB; Kothinti RK; Kamyshko I; Petering DH; Kumar S; Tabatabai NM
Diabetes Technol Ther; 2011 Jul; 13(7):743-51. PubMed ID: 21510766
[TBL] [Abstract][Full Text] [Related]
7. Structural selectivity of human SGLT inhibitors.
Hummel CS; Lu C; Liu J; Ghezzi C; Hirayama BA; Loo DD; Kepe V; Barrio JR; Wright EM
Am J Physiol Cell Physiol; 2012 Jan; 302(2):C373-82. PubMed ID: 21940664
[TBL] [Abstract][Full Text] [Related]
8. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
[TBL] [Abstract][Full Text] [Related]
9. Dual SGLT1/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis.
Martus G; Bergling K; Öberg CM
Perit Dial Int; 2023 Mar; 43(2):145-150. PubMed ID: 35188009
[TBL] [Abstract][Full Text] [Related]
10. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
11. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na
Coady MJ; Wallendorff B; Lapointe JY
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F467-F474. PubMed ID: 28592437
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic modeling for the effect of sodium-glucose cotransporter inhibitors on blood glucose level and renal glucose excretion in db/db mice.
Yamaguchi K; Kato M; Ozawa K; Kawai T; Yata T; Aso Y; Ishigai M; Ikeda S
J Pharm Sci; 2012 Nov; 101(11):4347-56. PubMed ID: 22927193
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
[TBL] [Abstract][Full Text] [Related]
16. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Dominguez Rieg JA; Rieg T
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):43-52. PubMed ID: 31081587
[TBL] [Abstract][Full Text] [Related]
17. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.
Kanwal A; Singh SP; Grover P; Banerjee SK
Anal Biochem; 2012 Oct; 429(1):70-5. PubMed ID: 22796500
[TBL] [Abstract][Full Text] [Related]
18. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters.
Pajor AM; Randolph KM; Kerner SA; Smith CD
J Pharmacol Exp Ther; 2008 Mar; 324(3):985-91. PubMed ID: 18063724
[TBL] [Abstract][Full Text] [Related]
20. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
Blaschek W
Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
